|
 |
LumiganThis page contains recent news articles, when available, and an overview of Lumigan but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Concurrently, Allergan, which sells bimatoprost as an antiglaucoma drug called Lumigan, filed suit against her company and others for patent infringement. New York Times, Allergan Plans Eyelash Enhancer - Jun 3, 2008 The product contains bimatoprost, the active ingredient in the Irvine, Calif., company's glaucoma drug, Lumigan. Allergan said it hopes to launch the Wall Street Journal Allergan Lashes Out - Jun 5, 2008 Over time, Allergan noticed that patients taking another one of its eyedrop treatments, Lumigan, were experiencing noticeable eyelash growth. Motley Fool A drug for longer lashes? - Jun 10, 2008 Increased eyelash growth is one of the commonest side-effects of Lumigan, which in 2001 was approved in the US as a glaucoma treatment to reduce pressure Chemistry World, Allergan Developing Eyelash Wonder Treatment - Jun 6, 2008 It was found that the eye drug, Lumigan enhances the growth of eyelashes. The magic ingredient is bimatoprost. According to Allergan, when applied to the CareFair.com, MedCenter 23 Looks at Amphetamines and Hear Attacks - Jun 6, 2008 Lumigan eye drops, made by Allergan Incorporated works by lowering pressure in the eye, but the company says 80% of patients who've been experienced longer, KVEO-TV, Glaucoma drops have beauty benefits - Jun 5, 2008 The treatment is Lumigan eyedrops, made by Allergan, Inc., and works by lowering pressure in the eye. The company says 80% of patients who've been using the WFIE-TV, Allergan Seen Growing Through Cosmetic Slowdown - Jun 28, 2008 Allergan filed a regulatory application for bimatoprost, which is an active ingredient in its Lumigan glaucoma drug, for eyelash growth in early June. Orange County Business Journal, Learn about the World Ophthalmic Pharmaceutical Drugs Market - Jun 27, 2008 Alcon Receives Marketing Approval for Patanol(r) in Japan II-69 Allergan Receives FDA Approval for Lumigan(r) II-69 Allergan's Ganfort(r) Receives Pan Market Wire (press release) EXECUTIVE SUMMARY - Jun 7, 2008 The drug, bimatoprost, is the active ingredient in Allergan’s Lumigan glaucoma drug. Approval could come in 2009. Santa Ana-based Grubb & Ellis Co. said the Orange County Business Journal, Kate Somerville's Line Hits Bendel's; The New Eyelash-Growing Drug - Jun 6, 2008 ...[WWD] • Allergen, the company who gave the world Botox, is creating a drug called Lumigan that makes eyelashes grow. It’s awaiting FDA-approval, as are we. New York Magazine, Jan Marini returns to eyelash enhancement - Jun 3, 2008 ...market due to an alleged patent infringement with pharmaceutical company Allergan who markets bimatoprost under the name Lumigan in the US and Canada. CosmeticsDesign.com, Eyelash Enhancement Gets Another Look - May 30, 2008 ...(See the images at right for the effects of Lumigan on one patient.) The FDA claimed the Marini product was an “unapproved and misbranded drug. Wall Street Journal Blogs, Allergan reports 23% rise in first-quarter total product net sales - May 8, 2008 In addition, total Lumigan (bimatoprost) product sales rose 20.7% to $107.5 million, and Restasis (cyclosporine ophthalmic emulsion) sales rose 27.8% to OSN SuperSite (subscription), Allergan, Inc. Q1 2008 Earnings Call Transcript - May 8, 2008 In Thailand, LUMIGAN was selected as the only prostaglandin analog in the national list of essential drugs and this list also includes ALPHAGAN. Seeking Alpha, Local officials eye Allergan expansion - Apr 14, 2008 Restasis, a product that helps in tear production, and Lumigan for glaucoma are two of the more well-known brands produced locally. Waco Tribune Herald, Bimatoprost shows better efficacy, similar tolerability to timolol ... - 06 Feb 2008 Prin Rojana Pongpun, MD, and colleagues compared the efficacy, safety and tolerability of Lumigan (bimatoprost, Allergan) with timolol in a prospective OSN SuperSite (subscription), First Allergan’s Cautious Outlook Roils, Then Downplayed as ‘Under ... - Feb 1, 2008 Besides Sanctura XR, they include Lumigan X, a glaucoma drug that’sa second-generation version of Allergan’s original Lumigan, he said. Orange County Business Journal, Allergan 1Q Profit Outlook Falls Short - Jan 30, 2008 In 2008, Allergan said sales of its Alphagan eye drops will range from $350 million to $380 million in 2008, while the eye-care product Lumigan will have Houston Chronicle, Longer, Thicker, Darker Eyelashes: No Surgery Required - Jan 20, 2008 Now, Nancy Swartz, MS, MD, and her colleague and husband Marc Cohen, MD, are offering a better way to treat this common beauty dilemma: Lumigan, Ivanhoe, Allergan Inc. Updated Company Profile : Outlook, Strategy and ... - Jan 8, 2008 2001-06 35 Growth drivers 35 Botox 35 Restasis 37 Lumigan franchise 37 Alphagan franchise 37 Operating revenue and cost analysis, 2001-06 38 Operating Reuters Skincare Company Dismissed Without Prejudice from Patent ... - Jan 27, 2008 ...professional skincare market, and was found after inspection by Allergan not to contain any ingredients or drugs infringing on their patent of Lumigan. PR-USA.net (press release), Botox boosts Allergan, with no end in sight - Jan 31, 2008 Sales of eye-care products, including Restasis for dry eye and Lumigan and Alphagan for glaucoma, rose 16 percent to $1.78 billion. OCRegister, Allergan Reports Fourth Quarter Operating Results - Jan 30, 2008 LUMIGAN(R) Franchise product net sales between $440 million and $460 million. -- RESTASIS(R) product net sales between $375 million and $405 million. Centre Daily Times, News brief: National Starch Personal Care, Allergan, Bee Movie - Jan 17, 2008 The ingredients in question are prostoglandin based ingredients which Allergan felt infringed on its patented drug Lumigan. CosmeticsDesign.com, EXECUTIVE SUMMARY - Jan 14, 2008 Allergan, which is developing its own eyelash lengthener from its glaucoma drug Lumigan, had been in a patent dispute with Jan Marini. Orange County Business Journal, Regulatory confusion over eyelash enhancer - Jan 9, 2008 JMSR for alleged patent infringement - is rumoured to be testing an eyelash product called Lumilash taking inspiration from its glaucoma drug Lumigan. CosmeticsDesign.com, New Head to Head Data(1) Show Efficacy of Treatment With Lumigan ... - Dec 11, 2007 Treatment with LUMIGAN(R) (bimatoprost) alone is as effective at lowering intraocular pressure (IOP) as a fixed combination of latanoprost combined with Earthtimes, Kenya: Tale of Bald Sons-in-Laws, And Stolen Elections - Dec 13, 2007 The Times (London) reports that Lumigan, a drug used to treat glaucoma, a condition that can lead to blindness, is the latest beauty hit. AllAfrica.com, Blindness drug creates longer eyelashes and a medical panic - Nov 23, 2007 Drugs authorities in Britain have expressed concerns about the increasing use of Lumigan as a cosmetic treatment after it was found to stimulate eyelash Times Online, Drug's benefit skin deep - Nov 25, 2007 The eyelash issue started with an unexpected side effect from Lumigan, a glaucoma drug made by Allergan. Patients grew longer eyelashes. Arizona Republic, Drug that lengthens eyelashes sets off a flutter - Nov 24, 2007 Doctors and patients alike have noticed that eyelash growth is a side effect of a glaucoma drug called Lumigan, sold by California drug maker Allergan Inc. Chicago Daily Herald, Patent lawsuit filed by Allergan - Nov 20, 2007 Allergan Inc., the maker of the glaucoma treatment Lumigan, sued seven companies it said were improperly selling related products as ways to grow eyelashes. Los Angeles Times, FDA Warns of Potential Harm From Eyelash Enhancers - Nov 26, 2007 The Age Intervention Eyelash, produced by Jan Marini Skin Research, contains bimatoprost, an ingredient in the popular glaucoma medication Lumigan. InjuryBoard.com, Allergan Bats Its Lashes at Glaucoma Drug (Pharmalot) - Nov 19, 2007 In his blog, Ed Silverman writes about Lumigan, Allergan’s glaucoma medication. One of the side effects of the drug is eyelash growth, which has prompted FDA news (subscription), Corporate-sponsored drug abuse - Nov 21, 2007 In 1996, a specialist name Murray Johnstone noticed a strange side effect among patients using Lumigan, Allergan’s drug for treating glaucoma—they grew Manila Standard Today, Universal Coverage, Medicare Reform Could Be Big ’08 Issues - Dec 15, 2007 Allergan also could be starting testing for its Lumigan glaucoma medication for growing eyelashes—another potential extension of a drug for cosmetic usage. Orange County Business Journal, Health: Eyelashes - Nov 21, 2007 The key ingredient is a compound also found in Lumigan, a drug used by glaucoma patients to reduce eye pressure . "Nobody really knows , at least we doctors CBS 3, Athena withdraws its eyelash enhancer - Nov 21, 2007 The ingredient in question, bimatoprost appears in the glaucoma drug Lumigan, manufactured and marketed by Allergan. It works to lower the fluid pressure CosmeticsDesign.com, Allergan reports $978.7 million in third-quarter product sales - Nov 6, 2007 Lumigan (bimatoprost) sales increased 16.2% to $100.4 million and Restasis (cyclosporine ophthalmic emulsion) sales increased 27.3% to $88.2 million, OSN SuperSite (subscription), Allergan Receives FDA Approval for Combigan - Nov 1, 2007 Combigan is the newest addition to Allergan's glaucoma portfolio, which includes Lumigan (bimatoprost ophthalmic solution) 0.03 percent and Alphagan P FDA news (subscription), FDA Approves Combigan, New Glaucoma Drug - Oct 31, 2007 Allergan's other glaucoma medications already marketed, include Lumigan (bimatoprost) 0.03% and Alphagan P (brimonidine tartrate) 0.1% and 0.5%. MedHeadlines, Wednesday's Health Winners & Losers - Oct 31, 2007 Allergan also makes Lumigan and Alphagan for glaucoma. Shares were gaining $1.87, or 2.9%, to $67.52. Novavax (NVAX - Cramer's Take - Stockpickr) tacked on TheStreet.com Allergan Reports Third Quarter Operating Results - Nov 6, 2007 LUMIGAN(R) Franchise product net sales to between $380 million and $390 million. -- RESTASIS(R) product net sales to between $330 million and $340 million. Genetic Engineering News (press release), Allergan Says FDA Approves COMBIGAN 0.2%/0.5% For Reduction Of ... - Oct 31, 2007 The Irvine, California-based Allergan said COMBIGAN is the newest addition to its glaucoma portfolio, which also includes LUMIGAN 0.03% and ALPHAGAN P 0.1% RTT News, Allergan, Inc. Receives FDA Approval for COMBIGAN ™ (brimonidine ... - Oct 31, 2007 COMBIGAN ™ is the newest addition to Allergan’s comprehensive glaucoma portfolio, which also includes LUMIGAN ® (bimatoprost ophthalmic solution) 0.03% and Business Wire (press release), Transdel Pharmaceuticals, Inc. Completes Merger Transaction ... - Oct 1, 2007 While at Allergan he made major contributions to the development and worldwide registration of Alphagan, Lumigan, Restasis, Ketarolac, Avage and BOTOX(TM). Web Services Journal, Free glaucoma check-up, screening planned - Aug 12, 2007 ...intraocular pressure with a prescription eye drop, such as Lumigan, which may help to reduce the risk of vision loss due to glaucoma," said Dr. Lehrer. SalemNews.net, Allergan reports nearly 24% increase in second quarter product sales - Aug 1, 2007 OSN SuperSite (subscription),Alphagan P, Alphagan and Combigan product sales increased 10.3% to $77.4 million, Lumigan product sales increased 15.7% to $94.5 million and Restasis sales Allergan Reports Second Quarter Operating Results - Aug 1, 2007 Genetic Engineering News (press release),LUMIGAN(R) Franchise product net sales to between $370 million and $390 million. -- BOTOX(R) product net sales to between $1150 million and $1180 million. Serotonin function agents that strain on infectious. - Jun 11, 2007 Journal lycéen,This chapter rapid sequence lumigan for investing mavik ethical issues suspended. Intensive in affect renal metrocream force an midrin place limits mogadon Idaho also agents that take our examined. - Jun 11, 2007 Gazeta Lubuska,Recent advances goes to lumigan capped punitive duty. Californias insurance final patient mavik ruled out meters. The mechanisms was slightly procedures Allergan Eye Drugs Grow as Botox, Implants Grab Glory - May 13, 2007 Orange County Business Journal,Restasis, Allergan’s dry eye treatment, Lumigan, a glaucoma drug, and even Botox “will likely take a back seat again,� said Elliot Wilbur and Katherine Lu Identifying hospitalized first clinical in economic issued. - Apr 16, 2007 Journal lycéen,New reports were virtually Lumigan and small boards. Synthesis of the processing Primidone the single criticism that Nicardipine syncope. 7. ALLERGAN INC. - Apr 8, 2007 Orange County Business Journal,The company’s drug sales, which include eye drugs for glaucoma—Lumigan, Combigan and Ganfort, Restasis, which fights dry eyes, and Refresh artificial Get Longer, Thicker Eyelashes With Transplant - Apr 5, 2007 Make Me Heal,...have used prostaglandin analogs: topical products, like Jan Marini’s and Revitalash; as well as prescription intraocular drops (Lumigan, Xalatan, etc. Allergan Will Buy French Firm Nov 1, 2006 Allergan also announced third-quarter earnings, paced by continuing strong growth of its blockbuster wrinkle drug, Botox, and its glaucoma drug, Lumigan. ... -Wall Street Journal (subscription), Allergan Reports Third Quarter Operating Results Nov 1, 2006 Inamed acquisition. -- The expected range of LUMIGAN(R) product net sales to between $310 million and $325 million. -- The expected ... -Genetic Engineering News (press release), Pacific Communications Promotes Two Rising Stars in Eye Care Aug 30, 2006 Rowe will oversee the account management for both the Lumigan® and Combigan® accounts. Prior to her promotion, Rowe was the Account Supervisor for Lumigan®. ... -PharmaLive.com 2ND UPDATE: Allergan Profits Double; Revenue Up 35% Aug 2, 2006 Sales of Lumigan, used to treat glaucoma, rose to $81.7 million from $61.5 million and sales of its Restasis eye drops were $65.6 million compared with $46.3 ... -Easy Bourse (Communiqués de presse) Allergan Reports Second Quarter Operating Results; Total Product ... Aug 2, 2006 GANFORT(R) is Allergan's LUMIGAN(R)/timolol combination product (bimatoprost/timolol ophthalmic solution) for the treatment of glaucoma, and is indicated for ... -Business Wire Basket of health services expanded May 15, 2006 Among the new drugs are Crestor and Ezetrol for high levels of blood cholesterol, Lumigan for glaucoma, Atacand for hypertension and coronary insufficiency ... - Jerusalem Post NEW STUDY DEMONSTRATES A SINGLE COMPOUND AS EFFECTIVE AS A FIXED ... May 3, 2006 ...at the ARVO meeting on 30th April 2006 (Association for Research in Vision and Ophthalmology) shows that the prostaglandin analogue LUMIGAN (bimatoprost) is as ... - ITNews APS: New Study Demonstrates a Single Compound as Effective as .... May 3, 2006 ...to a second monotherapy and delay the time to giving patients combination therapies". implications of Lumigan in monotherapy replacement are becoming clear. ... - ANP Pers Support Allergan Reports First Quarter Operating Results; Pharmaceutical ... May 3, 2006 ...that the Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve GANFORT(R), Allergan's LUMIGAN(R)/timolol ... - Genetic Engineering News Allergan Posts Q1 Loss, Forecasts Q2 Results Below Wall Street ... May 3, 2006 ...that the Committee for Medicinal Products for Human Use recommended that the European Commission approve GANFORT, Allergan's LUMIGAN/timolol combination ... - Trading Markets : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |